Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Norihiro Sakurai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan. Hauptthemen laut MEDLINE: Linezolid, Thrombocytopenia, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Linezolid is a widely used antimicrobial agent in clinical practice; however, its usage is often limited by linezolid‐induced thrombocytopenia (LIT). While prior studies have assessed linezolid plasma concentrations, the clinical relevance of its metabolites, PNU‐142300 and PNU‐142586, remains unclear. This study aimed to investigate the association between these metabolite concentrations and LIT, and to identify predictive thresholds. This study retrospectively analyzed patients treated with linezolid at Osaka Metropolitan University Hospital between January 2017 and December 2024. Patient characteristics, trough concentrations (C trough ), AUC 24 , and pharmacokinetic parameters of linezolid and its metabolites were compared among patients with and without thrombocytopenia. Receiver operating characteristic (ROC) analysis identified thresholds for LIT prediction. Risk factors were assessed using multivariate logistic regression analysis. Forty‐eight patients were included, with thrombocytopenia developing in 26 patients (54.2%). C trough and AUC 24 of PNU‐142300 and PNU‐142586 were significantly higher in the thrombocytopenia group; meanwhile, linezolid C trough and AUC 24 did not differ significantly. ROC analysis identified C trough ≥1.43 µg/mL and AUC 24 ≥37.8 mg h/L for PNU‐142586 as predictive thresholds. Multivariate analysis revealed that linezolid therapy ≥14 days (OR = 9.53, P = .044) and PNU‐142586 C trough ≥1.43 µg/mL (OR = 37.60, P = .002) as independent risk factors. Elevated PNU‐142586 concentrations were associated with a higher cumulative incidence of LIT. Accumulation of linezolid metabolites, especially PNU‐142586, is closely associated with LIT. Monitoring of PNU‐142586 may improve the safety of linezolid therapy and support individualized dosing strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
- Department of Pharmacy, Osaka Metropolitan University Hospital, Abeno-ku, Osaka, Japan.
- Department of Infection Control, Osaka Metropolitan University Hospital, Abeno-ku, Osaka, Japan.
- Department of Pharmacy, Tazuke Kofukai Medical Research Institute, Kitano Hospital, Kita-ku, Osaka, Japan.
- Research Center for Infectious Disease Sciences (RCIDS), Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
- Osaka International Research Center for Infectious Diseases (OIRCID), Osaka Metropolitan University, Abeno-ku, Osaka, Japan.
ORCID-Profile: Norihiro Sakurai
Zitieren
APA
Sakurai, N., Kawaguchi, H., Matsui, T., Nishiura, H., Kobayashi, K., Imoto, W., Shibata, W., Nakamura, Y., & Kakeya, H. (2025). Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70124
Vancouver
Sakurai N, Kawaguchi H, Matsui T, Nishiura H, Kobayashi K, Imoto W, et al. Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70124
BibTeX
@article{Sakurai2025,
author = {Sakurai, Norihiro and Kawaguchi, Hiroshi and Matsui, Toya and Nishiura, Hironobu and Kobayashi, Kazuhiro and Imoto, Waki and Shibata, Wataru and Nakamura, Yasutaka and Kakeya, Hiroshi},
title = {Evaluating the Impact of Linezolid Metabolites: PNU‐142300 and PNU‐142586 on the Development of Linezolid‐Induced Thrombocytopenia in Adult Patients},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70124}
}
EUVIMED